Alnylam Pharmaceuticals Inc “RNAi Roundtable” Webcast Series: Patisiran & Vutrisiran, in Development for the Treatment of Transthyretin-Mediated Amyloidosis Transcript
Good afternoon, everyone. Thank you for joining us today for this RNAi Roundtable, where we'll be discussing patisiran and vutrisiran development for the treatment of transthyretin-mediated amyloidosis. I'm Christine Lindenboom, Senior Vice President of Investor Relations and Corporate Communications at Alnylam.
With me today are Eric Green, Senior Vice President and General Manager of the TTR program; John Vest, Vice President of Clinical Research; Rena Denoncourt, Senior Director and Program Leader of the vutrisiran program; and Dr. Nitasha Sarswat, Director of the Infiltrative Cardiomyopathy Program at the University of Chicago Hospital.
Before I hand it over to Eric, I'll start with a few brief comments. Today's RNAi Roundtable is the fourth in a series of roundtable webinars that we've been hosting over the past few months to review progress across our various programs. Today's event is expected to run approximately 75 minutes. Eric will moderate a Q&A session at the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
